Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 44

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 44
---
 hold the 2025 Annual Meeting of Stockholders more than 30 days before or after the one-year anniversary date of the Annual Meeting, then notice must be provided by the later of 60 calendar days prior to the date of the annual meeting or the 10 th calendar day following the day on which public announcement of the date of the annual meeting is first made by us.

**Nomination of Director Candidates for Inclusion in Proxy Materials (Proxy Access)**

In addition to the timing requirements referenced above, for any stockholder proposal or director nomination to be considered at the 2025 Annual Meeting of Stockholders, the notice to our Corporate Secretary must contain certain information concerning the matters or nominations to be brought before such meeting and the stockholder proposing such matters. These requirements are more fully described in our Bylaws. We will not entertain any proposals or nominations at the 2025 Annual Meeting of Stockholders that do not meet the additional requirements set forth in our Bylaws.

Further, even if a stockholder’s proposal is included in our proxy materials for the 2025 Annual Meeting of Stockholders, if such stockholder does not also comply with the requirements of Rule 14a-4(c)(2) under the Exchange Act, we may exercise discretionary voting authority under proxies that we solicit to vote in accordance with our best judgement on any such stockholder proposal or nomination.

#### Other Matters
We know of no other matters to be submitted at the Special Meeting of stockholders. If any other matters properly come before the Special Meeting of stockholders, it is the intention of the proxy holders to vote the shares they represent as the Board may recommend.

### WHERE YOU CAN FIND MORE INFORMATION
This proxy statement under Section 14(a) of the Exchange Act contains a notice of meeting with respect to the Special Meeting at which the Company’s stockholders will consider and vote upon the proposals described herein.

<div align='center'>25</div>

#### TABLE OF CONTENTS
The Company files reports, proxy statements and other information with the SEC as required by the Exchange Act. You can find the Company’s electronically filed reports, proxy, information statements and additional business and financial information about the Company included in documents previously filed by the Company with the SEC on the SEC’s website without charge at http://www.sec.gov or on the Company’s website at https:// https://plustherapeutics.com/. Information included on the Company’s website is not a part of this proxy statement.

You should rely only on the information contained in this proxy statement. The Company has